Physician profile
Conner Kapperman
NPI 1356961213
$3,292.50
in general payments reported to CMS, 2019-2025
22 companies · $973 in 2025
The $973 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $452 · 2021: $78.00 · 2022: $247 · 2023: $432 · 2024: $1,111 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,515.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $820.43 | 2022-2025 | Miebo, Vyzulta, Infuse |
| Tarsus Pharmaceuticals, INC. | $372.19 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $361.74 | 2023-2025 | Precision 1, Dailies Total1, Total30 |
| Sun Pharmaceutical Industries INC. | $238.67 | 2020-2025 | |
| Coopervision INC. | $223.23 | 2023-2025 | Myday Contact Lens |
| Oyster Point Pharma, INC. | $175.21 | 2022-2025 | Tyrvaya |
| The Cameron-Ehlen Group, INC. | $146.21 | 2020 | |
| Mallinckrodt Hospital Products INC. | $142.94 | 2022-2025 | Acthar |
| Allergan, INC. | $133.39 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $120.73 | 2020 | |
| Abb Con-Cise Optical Group LLC | $119.59 | 2025 | Contact Lens |
| Johnson & Johnson Vision Care, INC. | $114.26 | 2024 | |
| Abbvie INC. | $66.00 | 2023-2025 | |
| Carl Zeiss Meditec USA, INC. | $59.98 | 2024 | Cirrus Hd-Oct |
| Rxsight INC | $36.97 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $36.54 | 2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $33.85 | 2020-2021 | |
| Thea Pharma INC. | $24.33 | 2024 | Iyuzeh |
| Horizon Therapeutics Plc | $21.38 | 2023 | Tepezza |
| Lkc Technologies, INC. | $16.44 | 2025 | |
| Novartis Pharmaceuticals Corporation | $14.31 | 2021 | |
| Tearlab Corp | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conner Kapperman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.